Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Hearings in July and the fall will follow, but if the first session was any indication, industry doesn't have anything to worry about.
Latest From Pricing Debate
The government is expecting to reap UK-wide savings of £33m by basing the statutory drug pricing scheme on regular payments on sales rather than price cuts and limiting the maximum prices companies can charge the NHS. The move will bring the scheme more into line with the voluntary PPRS.
Biopharma industry's arguments on rebate pass-through to patients appear to carry the day at Senate HELP Committee hearing.
Oncologists charge at least 50% more for Lupron and Aranesp than do urologists or nephrologists, researchers with Johns Hopkins and Memorial Sloan Kettering found.
Generic competition is nearing for hepatitis C medicines formulated with Gilead’s sofosbuvir in Chile, following moves by the health ministry to allow compulsory licensing.
Panel recommends National Academies of Sciences evaluate value frameworks like ICER, identify limitations and strengths and, if necessary, develop a new approach.
Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.
Sanofi/Regeneron reveal plans to lower price of PCSK9 blocker Praluent to match ICER's updated recommendation, following assessment based on new outcomes data. Decision sparks debate across industry and raises questions about setting precedent on pricing for the future.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.